Latest news

• Novartis doubles down on biosimilars with Biocon alliance

  In the last couple of years it has picked up approvals for Rixathon - a biosimilar of Roche’s cancer and arthritis drug MabThera (rituximab) - as well as its Erelzi version of

• Alcon's return to growth gives Novartis 'options', says CEO

  Novartis said the recent approval and launch of two biosimilar drugs in the EU - Erelzi (etanercept) to treat immunological diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis and Rixathon (rituximab)

• Sanofi and Regeneron bag EU approval for arthritis drug Kevzara

  from the EMA for Erelzi, its version of Enbrel that has also been approved by the FDA.

• Novartis says its biosimilar sales should reach $1bn this year

  Generics subsidiary Sandoz has also claimed the first US approval for its biosimilar version of Amgen's anti-TNF drug Enbrel (etanercept) - which will be sold as Erelzi - although a launch

• Novartis claims first place for its biosimilar Enbrel in US

  However, Amgen’s patent infringement lawsuit could delay the launch of Erelzi. ... Sandoz's drug - called Erelzi - has been approved for all the indications covered in the label for Enbrel (etanercept), including rheumatoid arthritis, psoriasis,